盐酸氨溴索联合布地奈德治疗支气管肺炎对患儿肺功能及血清IL-6、IL-8、CRP水平的影响

Effect of ambroxol hydrochloride combined with budesonide on lung function and serum IL-6, IL-8 and CRP levels in children with bronchopneumonia

目的 研究盐酸氨溴索联合布地奈德治疗支气管肺炎对患儿肺功能及血清白细胞介素-6(IL-6)、白细胞介素-8(IL-8)、C反应蛋白(CRP)水平的影响。方法 110例支气管肺炎患儿,按照随机数字表法分为对照组和观察组,每组55例。对照组患儿采用吸入用布地奈德混悬液雾化吸入治疗,观察组患儿在对照组基础上联合盐酸氨溴索分散片口服治疗。比较两组患儿治疗后症状(咳嗽、气促、喘鸣音、湿啰音)消失时间,治疗前后肺功能指标[用力肺活量(FVC)、呼气峰值流速(PEF)、第1秒用力呼气容积(FEV1)]水平,治疗前后血清IL-6、IL-8、CRP水平。结果 治疗后,观察组患儿的咳嗽、气促、喘鸣音、湿啰音消失时间分别为(5.01±1.08)、(2.31±1.05)、(3.33±1.21)、(4.14±1.13)d,均短于对照组的(6.37±1.45)、(4.15±1.62)、(4.26±1.75)、(5.97±2.11)d,差异有统计学意义(P<0.05)。治疗后,两组FVC、FEV1、PEF水平均较治疗前升高,且观察组FVC(4.54±0.73)L、FEV1(3.54±0.65)L、PEF(6.87±0.52)L/s均高于对照组的(3.03±0.64)L、(2.11±0.57)L、(5.37±0.95)L/s,差异有统计学意义(P<0.05)。治疗后,两组血清IL-6、IL-8、CRP水平均较治疗前降低,且观察组血清IL-6(23.28±6.31)ng/L、IL-8(20.32±3.73)μg/L、CRP(10.73±3.26)mg/L均低于对照组的(35.89±7.24)ng/L、(31.76±2.17)μg/L、(21.46±2.42)mg/L,差异有统计学意义(P<0.05)。结论 支气管肺炎患儿采用盐酸氨溴索联合布地奈德治疗,可对患儿体内的炎性因子水平发挥抑制作用,还可有效改善其肺部功能,缩短其临床症状的恢复时间,最终达到缓解病情进展的目的。

Objective To study the effect of ambroxol hydrochloride combined with budesonide on lung function and serum interleukin-6(IL-6), interleukin-8(IL-8), C-reactive protein(CRP) levels in children with bronchopneumonia. Methods A total of 110 children with bronchopneumonia were divided into a control group and an observation group according to the random numerical table, with 55 cases in each group. Children in the control group were treated by atomization inhalation of budesonide suspension for inhalation, and children in the observation group were treated by oral administration of ambroxol hydrochloride dispersible tablets on the basis of the control group. Both groups were compared in terms of disappearance time of symptoms(cough, shortness of breath, wheezing and wet rales) after treatment, the levels of pulmonary function indexes [force vital capacity(FVC), peak expiratory flow rate(PEF), forced expiratory volume in one second(FEV1)], the levels of serum IL-6, IL-8 and CRP before and after treatment. Results After treatment,the disappearance time of cough, shortness of breath, wheezing and wet rales in the observation group were(5.01±1.08),(2.31±1.05),(3.33±1.21) and(4.14±1.13) d, which were shorter than(6.37±1.45),(4.15±1.62),(4.26±1.75) and(5.97±2.11) d in the control group, and the differences were statistically significant(P<0.05).After treatment, the FVC, FEV1 and PEF levels in both groups were higher than those before treatment in this group;the FVC(4.54±0.73) L, FEV1(3.54±0.65) L and PEF(6.87±0.52) L/s in the observation group were higher than(3.03±0.64) L,(2.11±0.57) L and(5.37±0.95) L/s in the control group;the differences were statistically significant(P<0.05). After treatment, the levels of serum IL-6, IL-8 and CRP in both groups were lower than those before treatment in this group;the serum IL-6(23.28±6.31) ng/L, IL-8(20.32±3.73) μg/L and CRP(10.73±3.26) mg/L in the observation group were lower than(35.89±7.24) ng/L,(31.76±2.17) μg/L,and(21.46±2.42) mg/L in the control group;the differences were statistically significant(P<0.05). Conclusion Ambroxol hydrochloride combined with budesonide can not only inhibit the levels of inflammatory factors in children with bronchopneumonia, but also effectively improve their lung function and shorten the recovery time of clinical symptoms, and ultimately achieve the purpose of relieving the progression of the disease.